Ann: Incannex to Prepare IND Application for Psi-GAD, page-5

This moment is to me a clear-cut case of 'be greedy when others are fearful'.

Years of preparation now see formidable duck after formidable duck lining up to unleash the real deal news flow in time for full exposure to the US market. In a few months, with the combination of IHL-42x pivotal trials underway, results for PsiGAD phase 2 and opening IND for same, Clarion clinics opening their doors, IHL675a phase 2 trial commencing... Incannex will start to take its well-deserved place in the sector.

Last but not least, and as if the above were not enough, I believe IHL216a formulation for Traumatic Brain Injury may well start human clinical trials within the same time frame: a perfect exposure vehicle for the US market. I hope the BOD puts together some bespoke PR around that program when the time comes. Quidel crushed it in 2020, messaging with the NFL how their covid tests were saving American football from shutting down. As IHL216a develops, Incannex will have many opportunities to communicate what this therapy could represent for every contact sport participant in the world, armed forces, etc. Should IHL216a make it to FDA approval, the case would be made for an inhaler finding its place in the med kits of every organization on earth.

2024 is going to be interesting.